1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Roche's Kadcyla set for EU launch, perhaps in Germany

 
• By Gemma Collier

Roche is preparing to launch HER2 positive breast cancer antibody-drug conjugate Kadcyla (trastuzumab emtansine) in Europe following approval from the European Commission.

Roche is preparing to launch HER2 positive breast cancer antibody-drug conjugate Kadcyla (trastuzumab emtansine) in Europe following approval from the European Commission.

The drug has been approved as a single agent for the treatment of adults with HER2 positive, unresectable locally advanced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.